JP2022533578A - Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画 - Google Patents

Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画 Download PDF

Info

Publication number
JP2022533578A
JP2022533578A JP2021566974A JP2021566974A JP2022533578A JP 2022533578 A JP2022533578 A JP 2022533578A JP 2021566974 A JP2021566974 A JP 2021566974A JP 2021566974 A JP2021566974 A JP 2021566974A JP 2022533578 A JP2022533578 A JP 2022533578A
Authority
JP
Japan
Prior art keywords
cancer
patient
treatment
tumor
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533578A5 (https=
Inventor
モロー，ミッシェル
ゲルマシェウスキ，フィオナ
グリッドン，ダニエル
レオン，キン－メイ
グラディナル，クリスティアン
シェパード，クリストファー
ホルツ，ジョセフィン－ビート
カイタリレ，ルイ
Original Assignee
エフ－スター セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by エフ－スター セラピューティクス リミテッド filed Critical エフ－スター セラピューティクス リミテッド
Publication of JP2022533578A publication Critical patent/JP2022533578A/ja
Publication of JP2022533578A5 publication Critical patent/JP2022533578A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021566974A 2019-05-14 2020-05-14 Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画 Pending JP2022533578A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1906807.1 2019-05-14
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB1914040.9 2019-09-30
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB2000318.2 2020-01-09
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (2)

Publication Number Publication Date
JP2022533578A true JP2022533578A (ja) 2022-07-25
JP2022533578A5 JP2022533578A5 (https=) 2023-05-17

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566974A Pending JP2022533578A (ja) 2019-05-14 2020-05-14 Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画

Country Status (12)

Country Link
US (1) US20220275092A1 (https=)
EP (1) EP3969477A1 (https=)
JP (1) JP2022533578A (https=)
KR (1) KR20220008316A (https=)
CN (1) CN114206939A (https=)
AU (1) AU2020275209A1 (https=)
BR (1) BR112021022831A2 (https=)
CA (1) CA3139003A1 (https=)
IL (1) IL287979A (https=)
MX (1) MX2021013943A (https=)
SG (1) SG11202112136RA (https=)
WO (1) WO2020229626A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7850884B2 (ja) * 2021-03-31 2026-04-24 メルス・ベー・フェー 新規多重特異性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220569A1 (en) * 2016-06-20 2017-12-28 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220569A1 (en) * 2016-06-20 2017-12-28 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"NCT03440437, FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Cont", CLINICALTRIALS.GOV ARCHIVE [ONLINE]，2019年01月26日，[RETRIEVED ON 2024 -4-16], JPN6024014995, ISSN: 0005456224 *

Also Published As

Publication number Publication date
WO2020229626A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04
US20220275092A1 (en) 2022-09-01
IL287979A (en) 2022-01-01
KR20220008316A (ko) 2022-01-20
CN114206939A (zh) 2022-03-18
EP3969477A1 (en) 2022-03-23
SG11202112136RA (en) 2021-11-29
BR112021022831A2 (pt) 2022-01-18
CA3139003A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP2022533578A (ja) Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
US11767361B2 (en) Method of treating lung cancer
Bagri et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
KR20210084560A (ko) Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
WO2022226637A1 (en) Method for allowing immune cells infiltration in tumors
JP2020507596A (ja) 膀胱癌の抗ｐｄ−ｌ１抗体治療
RU2818587C2 (ru) Режимы дозирования при введении биспецифичного антитела против lag -3/pd-l1
KR20250029883A (ko) 조합 요법
CA3217833A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
EP4470562A1 (en) Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel
WO2024194482A1 (en) Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗
JP2026501282A (ja) Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いて膵臓がんを処置する方法
WO2022198001A1 (en) Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
HK40013014A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2020081783A2 (en) Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240712

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241111